XML 53 R42.htm IDEA: XBRL DOCUMENT
v3.19.2

Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended |
--- | --- | --- | ---
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018
Other current assets | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Receivables from counterparty | $ 105 |  | $ 105 |  | $ 52
Other current assets | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Receivables from counterparty | 98 |  | 98 |  | 71
Other current assets | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Receivables from counterparty | 41 |  | 41 |  | 32
Accounts payable and accrued liabilities | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payables to counterparty | 605 |  | 605 |  | 405
Accounts payable and accrued liabilities | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payables to counterparty | 709 |  | 709 |  | 375
Other Noncurrent Liabilities | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payables to counterparty | 300 |  | 300 |  | 250
Other Noncurrent Liabilities | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payables to counterparty | 125 |  | 125 |  | 543
Other Noncurrent Liabilities | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Payables to counterparty | 375 |  | 375 |  | $ 375
Revenue | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total sales | 111 | $ 44 | 190 | $ 76 |
Revenue | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Total sales | 97 | 35 | 171 | 35 |
Revenue | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Net product sales recorded by Merck | 53 | 47 | 100 | 90 |
Merck’s profit share from sales in Bayer’s marketing territories | 51 | 28 | 94 | 53 |
Total sales | 104 | 75 | 194 | 143 |
Cost of sales | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 73 | 24 | 92 | 36 |
Cost of sales | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 23 | 1 | 74 | 1 |
Cost of sales | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 29 | 132 | 58 | 159 |
Selling, general and administrative | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 33 | 9 | 59 | 16 |
Selling, general and administrative | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 19 | 2 | 38 | 2 |
Selling, general and administrative | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 11 | 10 | 20 | 17 |
Research and development | AstraZeneca |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 33 | 42 | 78 | 71 |
Research and development | Eisai |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | 62 | 36 | 109 | 1,436 |
Research and development | Bayer AG |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |
Expenses | $ 32 | $ 28 | $ 62 | $ 56 |

X
- Definition Collaborative Arrangement, Expenses + References No definition available. + Details
Name: | mrk_CollaborativeArrangementExpenses
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Payable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementPayable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Profit Sharing + References No definition available. + Details
Name: | mrk_CollaborativeArrangementProfitSharing
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Receivable + References No definition available. + Details
Name: | mrk_CollaborativeArrangementReceivable
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative Arrangement, Revenues, Net of Commercialization Costs + References No definition available. + Details
Name: | mrk_CollaborativeArrangementRevenues
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement, Sales, Net + References No definition available. + Details
Name: | mrk_CollaborativeArrangementSalesNet
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_EisaiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mrk_BayerAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |